Alterations to the fibrinolytic enzyme system in patients with non- small cell lung carcinoma

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 5, 1999, Pages 261-267

  Pavey, S J ^a,c,d   Hawson, G A T ^b   Marsh, N A ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b REDCLIFFE HOSPITAL   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Fibrinolysis; Non small cell lung cancer; Plasminogen activator inhibitors; Plasminogen activators

Indexed keywords

ANTIPLASMIN; D DIMER; FIBRIN; PLASMA PROTEIN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTICLE; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; FIBRINOLYSIS; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TISSUE LEVEL;

EID: 0032791889     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199907000-00007     Document Type: Article

References (29)

1. 1. Cliffton EE, Grossi CE, Fibrinolytic activity of human tumours as measured by the fibrin plate method. Cancer 1955; 8: 1146-1154.
2. 2. Lund LR, Romer J, Thomasset N, Solberg H, Pyke C, Bissell MJ, et al. Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development 1996; 122: 181-193.
3. 3. Romer J, Bugge TH, Pyke C, Lund LR, Flick MJ, Degen JL, et al. Impaired wound healing in mice with a disrupted plasminogen gene. Nature Med 1996; 2: 287-292.
4. 4. Holst-Hansen C, Johannessen B, Hoyer-Hansen G, Römer J, Ellis V, Brunner N. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 1996; 14: 297-307.
5. 5. Xing RH, Rabbani SA. Over-expression of urokinase receptor in breast cancer cells results in increased tumour invasion, growth, and metastasis. Int J Cancer 1996; 67: 423-429.
6. 6. Soff GA, Sanderowitz J, Gately S, Verrusio E, Weiss I, Brem S, et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumour growth, tumour-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 1995; 96: 2593-2600.
7. 7. Stonelake PS, Jones CE, Neoptolemos JP, Baker PR. Proteinase inhibitors reduce basement membrane degradation by human breast cancer cell lines. Br J Cancer 1997; 75: 951-959.
8. 8. Skriver L, Larsson LI, Kielberg V, Nielsen LS, Andreason PA, Kristensen P, et al. Immunocytochemical localisation of urokinase-type plasminogen activator in Lewis lung carcinoma. J Cell Biol 1984; 99: 752-758.
9. 9. Buo L, Meling GI, Karlsrud TS, Johansen HT, Aasen AO. Antigen levels of urokinase plasminogen activator and its receptor at the tumour-host interface of colorectal adenocarcinomas are related to tumour aggressiveness. Human Pathol 1995; 26: 1133-1138.
10. 10. Sappino AP, Busso N, Belin D, Vassalli JD. Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res 1987; 47: 4043-4046.
11. 11. Oka T, Ishida T, Nishino T, Sugimachi K. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumours of pulmonary adenocarcinoma. Cancer Res 1991; 51: 3522-3525.
12. 12. Nagayama M, Sato A, Hayakawa H, Urano T, Takada Y, Takada A. Plasminogen activators and their inhibitors in non-small cell lung cancer. Cancer 1994; 73: 1398-1405.
13. 13. Pavey SJ, Butler D, Marsh NA, Ray MJ, Dare AJ, Hawson GAT. Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer. J Biol Res 1996; 122:331-339.
14. 14. Pedersen H, Brunner N, Francis D, Osterlind K, Ronne E, Hansen HH, et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994; 54: 4671-4675.
15. 15. Wojtukiewicz MZ, Zacharski LR, Moritz TE, Hur K, Edwards RL, Rickles FR. Prognostic significance of blood coagulation tests in carcinoma of the lung and colon. Blond Coag Fibrinol 1992; 3: 429-437.
16. 16. Buccheri G, Ferrigno D, Ginardi C, Zuliani C. Haemostatic abnormalities in lung cancer - prognostic implications. Eur J Cancer 1997; 33: 50-55.
17. 17. Seitz R, Rappe N, Draus M, Immel A, Wolf M, Maasberg M, et al. Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis. Blood Coag Fibrinol 1993; 4: 249-254.
18. 18. Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S. Evaluating prethrombotic state in lung cancer using molecular markers. Chest 1993; 103: 196-200.
19. 19. World Health Organization. The World Health Organization histological typing of lung tumours. Am J Clin Path 1982; 77: 123-136.
20. 20. Stitk FP. The new staging of lung cancer. Advances in chest radiology. Radiol Clin N Am 1994; 32: 635-647.
21. 21. Pedersen H, Grondahl-Hansen J, Francis D, Osterlind K, Hoi Hansen H, Dano K, et al. Urokinase and plasminogen activator inhibitory type 1 in pulmonary adenocarcinoma. Cancer Res 1994; 54: 120-123.
22. 22. Camiolo SM, Siuta MR, Madeja JM. Improved medium for extraction of plasminogen activator from tissue. Prep Biochem 1982; 12: 297-305.
23. 23. Meade TW, Chakrabarti R, Haines AP, North WRS, Stirling Y. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. BMJ 1979; i: 153-156.
24. 24. Mannucci PM, Mari D, Merati G, Peyvandi F, Tagliabue L, Sacchi E, et al. Gene polymorphisms predicting high plasma levels of coagulation and fibrinolysis proteins - a study in centenarians. Arterioscl Thromb Vasc Biol 1997; 17: 755-759.
25. 25. Nakstad B, Lyberg T. Immunohistochemical localization of coagulation, fibrinolytic and antifibrinolytic markers in adenocarcinoma of the lung. APMIS 1991; 99: 981-988.
26. 26. Pyke C, Kristensen P, Ralfkiaer E, Eriksen H, Danö K. The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumour stroma. Cancer Res 1991; 51: 4067-4071.
27. 27. Gris JC, Schved JF, Marty-Double C, Mauboussin JM, Balmes P. Immunohistochemical study of tumour cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas. Chest 1993; 104: 8-13.
28. 28. Pappot H, Pfeiffer P, Grondahl-Hansen J, Skov BG. Urokinase plasminogen activator, its inhibitor and receptor in non-small cell lung cancer and small cell lung cancer. Int J Oncol 1997; 10: 177-182.
29. 29. Marsh NA. Fibrinolysis. Chichester: John Wiley and Sons; 1981.